MOTS-c vs Sermorelin

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

MOTS-cSermorelin
CategoryPeptidesPeptides
Standard DoseResearch indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.
TimingMorning administration preferred. Can be dosed pre-workout for enhanced exercise performance.Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.
Cycle Duration8-16 week cycles.12-24 week cycles. Some protocols use continuous treatment.
Evidence LevelEmerging (strong preclinical)strong_human
A

MOTS-c

Peptides

Mechanism

MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.

Standard Dosing

Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.

Timing

Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.

Cycle Duration

8-16 week cycles.

Side Effects

  • Injection site reactions
  • Mild fatigue post-injection
  • Transient flushing
  • Muscle soreness (exercise-mimetic effect)

Contraindications

  • Pregnancy and breastfeeding
  • Type 1 diabetes (insulin sensitivity changes require monitoring)
  • Not FDA-approved
  • Limited human safety data
  • Active cancer (metabolic pathway activation)

Best Stacking Partners

5-Amino-1MQAOD-9604Semaglutide
B

Sermorelin

Peptides

Mechanism

Sermorelin is a synthetic 29-amino acid peptide representing the biologically active fragment of GHRH (amino acids 1-29) with full functional activity. It activates GHRH receptors on pituitary somatotrophs, stimulating cAMP production via Gs protein/adenylate cyclase and MAP kinase pathways. Due to the interactive effects of sermorelin and endogenous somatostatin, GH release is episodic rather than continuous. Sermorelin also stimulates pituitary gene transcription of GH mRNA, increasing and preserving pituitary GH reserve.

Standard Dosing

Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.

Timing

Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.

Cycle Duration

12-24 week cycles. Some protocols use continuous treatment.

Side Effects

  • Injection site reactions
  • Facial flushing
  • Headache
  • Dizziness
  • Transient taste changes

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Intracranial hypertension

Best Stacking Partners

IpamorelinGHRP-2GHRP-6

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →